OGN Organon & Co

Pomerantz LLP has filed a class action lawsuit against Organon & Co. (NYSE: OGN) on behalf of investors who suffered losses. The lawsuit alleges securities fraud after Organon lowered its dividend payout, leading to a significant drop in stock price. Investors have until July 22, 2025, to seek appointment as Lead Plaintiff.

Gilman Hill Asset Management LLC significantly reduced its stake in Organon & Co. (NYSE:OGN) by 87.3% in Q3, selling 177,746 shares to hold a remaining 25,935 shares valued at $277,000. Brokerage firms have a generally negative outlook on OGN, with a consensus "Reduce" rating and an average price target of $8.38. Despite a low valuation, a recent beat on Q3 EPS estimates, and a small quarterly dividend, institutional investors show mixed activity in their holdings of Organon stock.

Organon, a pharmaceutical company, has signed a virtual power purchase agreement (VPPA) with Schneider Electric. This agreement will enable Organon to source solar energy in Spain, supporting its sustainability goals. The deal highlights the increasing trend of corporations investing in renewable energy to reduce their carbon footprint.

Levi & Korsinsky, LLP has announced a securities lawsuit alert for investors who suffered losses in Organon & Co. (NYSE: OGN) following alleged securities fraud between October 31, 2024, and April 30, 2025. The lawsuit claims Organon disseminated false and misleading statements regarding capital allocation through quarterly dividends, concealing a debt reduction strategy that led to a 70% decrease in its dividend. This news resulted in a dramatic single-day stock price decline of over 27% on May 1, 2025, from $12.93 to $9.45 per share.

Seven analysts have issued an average "Reduce" rating for Organon & Co. (NYSE:OGN), with a consensus 12-month target price of $8.38. The company recently reported better-than-expected quarterly EPS but faces concerns over its high debt-to-equity ratio, with shares currently trading around $6.97.

TetraScience announced that Organon will deploy its Scientific Data Foundry to modernize quality control (QC) data management and streamline batch release testing operations, starting at Organon's Heist, Belgium manufacturing site. This collaboration aims to address challenges in biopharmaceutical quality testing by automating scientific data workflows, thereby reducing analysis time by up to 30% and enhancing data integrity. The initiative supports Organon's mission to deliver life-changing medicines faster and more safely by leveraging AI-native data and advanced telemetry for data-driven insights.